
Getinge AB (publ)
Getinge AB (publ) (GNGBY) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
gngby · pe ratio · data through Jun 10, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Medical - Devices · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Getinge AB (publ)You GNGBY | $5.5B | N/A | — | — |
Abbott Laboratories ABT | $157.6B | 33.55x | +29.3% | $3.73 |
Align Technology, Inc. ALGN | $12.8B | 27.60x | +6.4% | $5.66 |
Bio-Rad Laboratories, Inc. BIO | $7.9B | 10.87x | -58.1% | $27.87 |
Bruker Corporation BRKR | $8.6B | N/A | — | -$0.06 |
CONMED Corporation CNMD | $1.0B | 26.78x | +3.2% | $1.52 |
DexCom, Inc. DXCM | $29.6B | 30.97x | +19.3% | $2.14 |
Industry Average 5 peers with valid PE | — | 25.95x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Getinge AB (publ) (GNGBY) measures how much investors pay for each dollar of the company's trailing earnings. GNGBY's current PE ratio of N/A is calculated by dividing its stock price of $20.15 by its TTM earnings per share of —.
Frequently asked questions
GNGBY pe ratio · 6 questionsGNGBY's current PE ratio is N/A as of 2026-06-10, based on a stock price of $20.15 and TTM EPS of —. Data sourced from Financial Modeling Prep via GNGBY's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Getinge AB (publ) SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-10